Answers are grounded in this paper and cite their sources.
Case report shows guselkumab improves psoriasis in a melanoma patient during pembrolizumab treatment, suggesting implications for therapy.
Severe pembrolizumab-exacerbated psoriasis in a patient with disseminated stage IV melanoma posed a significant therapeutic challenge. Guselkumab resulted in rapid clinical improvement (PASI 12.3 to 3.1; DLQI 21 to 3), allowing pembrolizumab rechallenge without recurrence of severe psoriasis. This case highlights the potential role of IL-23 inhibition in immune checkpoint inhibitor-induced psoriasis while emphasising uncertainty surrounding oncological outcomes in this setting.
No takes yet. Share an insight, caveat, or question.
Conlon et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: